Urine-Based Assays for the Detection of Bladder Cancer
- 2 June 2009
- journal article
- review article
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 3 (3) , 265-274
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Furthermore, nonmuscle invasive bladder cancer has a 70% rate of recurrence, making it a considerable strain to the healthcare system. Patients with bladder cancer require repeat cystoscopic examinations of the bladder to monitor for tumor recurrence. The reason these patients have to undergo these costly, painful, invasive procedures is owing to the absence of accurate urine-based assays to detect the presence of bladder cancer noninvasively. Consequently, the development of a urine-based test to detect bladder cancer would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine markers in use today. In addition, the article will highlight some new technologies that are used to investigate novel urinary markers.Keywords
Funding Information
- Flight Attendant Medical Research Institute
This publication has 56 references indexed in Scilit:
- Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated UrotheliaCancer Epidemiology, Biomarkers & Prevention, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation StudyClinical Cancer Research, 2007
- Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic ProfilingJournal of Proteome Research, 2007
- Improved breast cancer prognosis through the combination of clinical and genetic markersBioinformatics, 2006
- Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladderBJU International, 2006
- A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical OutcomeClinical Cancer Research, 2005
- The Health Economics of Bladder CancerPharmacoEconomics, 2003
- COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER:Journal of Urology, 2002
- Identification of a nuclear protein matrixBiochemical and Biophysical Research Communications, 1974